182 related articles for article (PubMed ID: 24152721)
21. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a meta-analysis.
Zheng X; Yue P; Liu L; Tang C; Ma F; Zhang Y; Wang C; Duan H; Zhou K; Hua Y; Wu G; Li Y
PLoS One; 2019; 14(5):e0217274. PubMed ID: 31117119
[TBL] [Abstract][Full Text] [Related]
22. Kawasaki disease with a concomitant primary Epstein - Barr virus infection.
Rosenfeld N; Tasher D; Ovadia A; Abiri S; Dalal I
Pediatr Rheumatol Online J; 2020 Aug; 18(1):65. PubMed ID: 32787862
[TBL] [Abstract][Full Text] [Related]
23. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease.
Wang CL; Wu YT; Liu CA; Lin MW; Lee CJ; Huang LT; Yang KD
Pediatrics; 2003 Feb; 111(2):E140-7. PubMed ID: 12563087
[TBL] [Abstract][Full Text] [Related]
24. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
Dhanrajani A; Chan M; Pau S; Ellsworth J; Petty R; Guzman J
Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1536-1540. PubMed ID: 29287309
[TBL] [Abstract][Full Text] [Related]
25. Monocyte platelet aggregates in children with Kawasaki disease- a preliminary study from a tertiary care centre in North-West India.
Vignesh P; Rawat A; Shandilya JK; Singh Sachdeva MU; Ahluwalia J; Singh S
Pediatr Rheumatol Online J; 2021 Mar; 19(1):25. PubMed ID: 33712020
[TBL] [Abstract][Full Text] [Related]
26. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
Jibiki T; Kato I; Shiohama T; Abe K; Anzai S; Takeda N; Yamaguchi KI; Kanazawa M; Kurosaki T
Pediatr Int; 2011 Oct; 53(5):729-735. PubMed ID: 21342358
[TBL] [Abstract][Full Text] [Related]
27. [Dynamic study of platelets surface glycoprotein in Kawasaki disease].
Pang Y; Liang H; Yu S; Liu X; Wang Q; Tang F; Liu Y; Jiang L
Zhonghua Xue Ye Xue Za Zhi; 2002 Mar; 23(3):134-7. PubMed ID: 12015066
[TBL] [Abstract][Full Text] [Related]
28. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
Durongpisitkul K; Sangtawesin C; Khongphatthanayopthin A; Panamonta M; Sopontammarak S; Sittiwangkul R; Pongpanich B
Asian Pac J Allergy Immunol; 2006 Mar; 24(1):27-32. PubMed ID: 16913186
[TBL] [Abstract][Full Text] [Related]
29. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis and management of Kawasaki disease.
Rowley AH; Shulman ST
Expert Rev Anti Infect Ther; 2010 Feb; 8(2):197-203. PubMed ID: 20109049
[TBL] [Abstract][Full Text] [Related]
31. Microparticles and Kawasaki disease: a marker of vascular damage?
Guiducci S; Ricci L; Romano E; Ceccarelli C; Distler JH; Miniati I; Calabri GB; Distler O; Matucci Cerinic M; Falcini F
Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S121-5. PubMed ID: 21385556
[TBL] [Abstract][Full Text] [Related]
32. [Effects of intravenous immunoglobulin and aspirin treatment on the functions of circulating endothelial progenitor cells in children with Kawasaki disease].
Xu MG; Men LN; Zu Y; Zhao CY; Meng XC
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Dec; 13(12):966-9. PubMed ID: 22172261
[TBL] [Abstract][Full Text] [Related]
33. An Uncommon Complication of a Common Disease: Pneumatosis Intestinalis in an Infant with Kawasaki Disease.
Ferstenfeld I; Shemer A; Razon Y; Yeshayahu Y
Isr Med Assoc J; 2019 Nov; 21(11):763-765. PubMed ID: 31713369
[No Abstract] [Full Text] [Related]
34. IVIG reduced vascular oxidative stress in patients with Kawasaki disease.
Takatsuki S; Ito Y; Takeuchi D; Hoshida H; Nakayama T; Matsuura H; Saji T
Circ J; 2009 Jul; 73(7):1315-8. PubMed ID: 19436119
[TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S
Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904
[TBL] [Abstract][Full Text] [Related]
36. Haemolytic uraemic syndrome with peripheral gangrene and Kawasaki disease in a 15-month-old child.
Krishnamurthy S; Jagadeesh A; Chandrasekaran V; Mahadevan S; Rajesh NG
Paediatr Int Child Health; 2017 Feb; 37(1):70-73. PubMed ID: 26752398
[TBL] [Abstract][Full Text] [Related]
37. IgG levels in Kawasaki disease and its association with clinical outcomes.
Yamazaki-Nakashimada MA; Gámez-González LB; Murata C; Honda T; Yasukawa K; Hamada H
Clin Rheumatol; 2019 Mar; 38(3):749-754. PubMed ID: 30343342
[TBL] [Abstract][Full Text] [Related]
38. Acetylsalicylic acid for children with Kawasaki disease.
Sakulchit T; Benseler SM; Goldman RD
Can Fam Physician; 2017 Aug; 63(8):607-609. PubMed ID: 28807954
[No Abstract] [Full Text] [Related]
39. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[TBL] [Abstract][Full Text] [Related]
40. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
